Multiple endocrine neoplasia type 1: Clinical manifestations and management

Anathea C. Powell, Steven K. Libutti

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Multiple endocrine neoplasia type I (MEN-1) is an autosomal dominant syndrome associated with anterior pituitary, parathyroid, and enteropancreatic endocrine tumors as well as other endocrine and nonendocrine tumors [1]. MEN-1 is defined as the presence of two of three main MEN-1-related manifestations, or at least one manifestation plus a first degree relative with at least one MEN-1-related manifestation [1,2]. The estimated prevalence of MEN-1 ranges from 1 in 10,000 to 1 in 100,000 [3], with 43 and 94% penetrance of MEN-1 by ages 20 and 50, respectively [4].

Original languageEnglish (US)
Pages (from-to)287-302
Number of pages16
JournalCancer Treatment and Research
Volume153
DOIs
StatePublished - 2010

Fingerprint

Multiple Endocrine Neoplasia Type 1
Penetrance
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Multiple endocrine neoplasia type 1 : Clinical manifestations and management. / Powell, Anathea C.; Libutti, Steven K.

In: Cancer Treatment and Research, Vol. 153, 2010, p. 287-302.

Research output: Contribution to journalArticle

Powell, Anathea C. ; Libutti, Steven K. / Multiple endocrine neoplasia type 1 : Clinical manifestations and management. In: Cancer Treatment and Research. 2010 ; Vol. 153. pp. 287-302.
@article{b99975d921f2452f83489a68880103ca,
title = "Multiple endocrine neoplasia type 1: Clinical manifestations and management",
abstract = "Multiple endocrine neoplasia type I (MEN-1) is an autosomal dominant syndrome associated with anterior pituitary, parathyroid, and enteropancreatic endocrine tumors as well as other endocrine and nonendocrine tumors [1]. MEN-1 is defined as the presence of two of three main MEN-1-related manifestations, or at least one manifestation plus a first degree relative with at least one MEN-1-related manifestation [1,2]. The estimated prevalence of MEN-1 ranges from 1 in 10,000 to 1 in 100,000 [3], with 43 and 94{\%} penetrance of MEN-1 by ages 20 and 50, respectively [4].",
author = "Powell, {Anathea C.} and Libutti, {Steven K.}",
year = "2010",
doi = "10.1007/978-1-4419-0857-5_16",
language = "English (US)",
volume = "153",
pages = "287--302",
journal = "Cancer Treatment and Research",
issn = "0927-3042",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - Multiple endocrine neoplasia type 1

T2 - Clinical manifestations and management

AU - Powell, Anathea C.

AU - Libutti, Steven K.

PY - 2010

Y1 - 2010

N2 - Multiple endocrine neoplasia type I (MEN-1) is an autosomal dominant syndrome associated with anterior pituitary, parathyroid, and enteropancreatic endocrine tumors as well as other endocrine and nonendocrine tumors [1]. MEN-1 is defined as the presence of two of three main MEN-1-related manifestations, or at least one manifestation plus a first degree relative with at least one MEN-1-related manifestation [1,2]. The estimated prevalence of MEN-1 ranges from 1 in 10,000 to 1 in 100,000 [3], with 43 and 94% penetrance of MEN-1 by ages 20 and 50, respectively [4].

AB - Multiple endocrine neoplasia type I (MEN-1) is an autosomal dominant syndrome associated with anterior pituitary, parathyroid, and enteropancreatic endocrine tumors as well as other endocrine and nonendocrine tumors [1]. MEN-1 is defined as the presence of two of three main MEN-1-related manifestations, or at least one manifestation plus a first degree relative with at least one MEN-1-related manifestation [1,2]. The estimated prevalence of MEN-1 ranges from 1 in 10,000 to 1 in 100,000 [3], with 43 and 94% penetrance of MEN-1 by ages 20 and 50, respectively [4].

UR - http://www.scopus.com/inward/record.url?scp=77953654703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953654703&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-0857-5_16

DO - 10.1007/978-1-4419-0857-5_16

M3 - Article

C2 - 19957231

AN - SCOPUS:77953654703

VL - 153

SP - 287

EP - 302

JO - Cancer Treatment and Research

JF - Cancer Treatment and Research

SN - 0927-3042

ER -